India’s pharmaceutical industry has ambitions that extend far beyond its position as a major supplier of affordable medicines. With companies expanding into regulated international markets, advanced formulations and contract development, the sector is working towards a much larger global role.
But recent developments highlight an important question: can the industry strengthen its manufacturing systems and quality processes quickly enough to support its growth ambitions?
A report published on November 10 highlighted a study pointing to operational bottlenecks in India’s pharmaceutical industry. Incident backlogs and delayed investigations were identified as challenges that can affect production efficiency and the industry’s wider ambitions.
The issue is particularly important because pharmaceutical manufacturing depends on strict quality systems. A delay in investigating a production incident can affect manufacturing schedules, regulatory compliance and the ability to maintain consistent product standards.
Regulatory scrutiny is also increasing. The Union Health Ministry has proposed rules that would allow immediate suspension of manufacturing licences when government testing identifies specified critical quality failures, including problems involving impurities, sterility, active ingredient content or dissolution. The proposal is intended to reduce delays in regulatory action, but it remains subject to the government’s consultation and final notification process.
At the company level, Indian pharmaceutical businesses are also pursuing new international opportunities. Morepen Laboratories announced on November 9 that it had launched its first prescription generic medicine in the United States: Desloratadine Tablets USP, 5 mg. The launch marks an expansion beyond supplying active pharmaceutical ingredients into finished-dose medicines and distribution.
The company has also submitted an application to the US Food and Drug Administration for Sitagliptin tablets, which is currently under regulatory review.
Other Indian companies have reported encouraging quarterly performance. Sai Life Sciences recorded 23% revenue growth in the second quarter of FY27, while Gland Pharma reported a 58% increase in quarterly profit. These developments reflect activity across research services, manufacturing and pharmaceutical exports.
For India, the opportunity is substantial. The country has an established position in generic medicines and a growing presence in contract research, development and manufacturing. However, international expansion requires reliable production, strong compliance systems, research investment and the ability to meet demanding regulatory standards.
The next phase of growth will not be measured only by how many medicines Indian companies manufacture. It will also depend on how consistently they can deliver quality, innovation and trust.
India’s pharmaceutical future may ultimately be shaped by the strength of its systems as much as the scale of its factories.
